Adaptin Bio Inc (APTN)

$6.27 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Adaptin Bio, Inc. develops biotechnology products for the treatment of cancer and other diseases. The company develops bispecific antibody-based therapies using its BRiTE Platform technology. Its BRiTE Platform uses fully human bispecific antibodies to redirect patients' T cells to recognize and destroy tumor cells and facilitate the delivery of T cell-targeting agents across the blood-brain barrier. The company's product pipeline includes APTN-101, an EGFRvIII x CD3 bispecific T cell engager de...

Phone: 888 609 1498
Address:
3540 Toringdon Way, Suite 200 #250, Charlotte, United States
STACKD0E
STACKD0E Aug. 20 at 8:08 PM
$FLUX $ISPC $APTN $VTSI 👁
0 · Reply
BioTuesdays
BioTuesdays Jul. 14 at 3:13 PM
$APTN is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural trafficking ability of immune cells, the company’s proprietary bispecific T-cell engager platform is designed to transport therapeutic agents directly to intracerebral tumors. https://biotuesdays.com/2026/07/14/adaptin-bio-is-leveraging-immune-cell-hitchhiking-to-target-brain-tumors/
0 · Reply
Latest News on APTN
No data available.
STACKD0E
STACKD0E Aug. 20 at 8:08 PM
$FLUX $ISPC $APTN $VTSI 👁
0 · Reply
BioTuesdays
BioTuesdays Jul. 14 at 3:13 PM
$APTN is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural trafficking ability of immune cells, the company’s proprietary bispecific T-cell engager platform is designed to transport therapeutic agents directly to intracerebral tumors. https://biotuesdays.com/2026/07/14/adaptin-bio-is-leveraging-immune-cell-hitchhiking-to-target-brain-tumors/
0 · Reply